Impact of GLP-1 Receptor Agonists on Major Gastrointestinal Disorders for Type 2 Diabetes Mellitus: A Mixed Treatment Comparison Meta-Analysis

Table 3

GI AEs cumulative incidence and the probability that each treatment is associated with highest incidence.

Treatment	Nausea			Vomiting			Diarrhea
	Incidence % (95% CI)	SUCRA	Rank	Incidence % (95% CI)	SUCRA	Rank	Incidence % (95% CI)	SUCRA	Rank
EX10BID	37.13  (35.44, 38.84)	0.992	1	13.13  (11.94, 14.41)	0.850	1	10.19 (9.09, 11.39)	0.555	4
EX2QW	18.83 (15.97, 21.96)	0.511	5	7.30 (5.47, 9.51)	0.463	6	12.09 (9.78, 14.86)	0.727	2
EX5BID	30.99 (27.57, 34.57)	0.616	4	10.66 (8.42, 13.26)	0.700	2	9.61 (7.48, 12.11)	0.504	6
LIR0.6	12.47 (9.63, 15.79)	0.437	6	7.61 (5.39, 10.38)	0.576	5	12.47 (9.63, 15.79)	0.544	5
LIR1.2	19.76 (17.67, 21.99)	0.658	2	8.22 (6.81, 9.81)	0.624	4	11.94  (10.13, 13.93)	0.789	1
LIR1.8	21.20 (19.34, 23.15)	0.635	3	8.92 (7.65, 10.33)	0.643	3	12.52 (10.95, 14.22)	0.726	3
CT	3.86 (3.19, 4.63)	0.001	8	2.19 (1.69, 2.80)	0.065	8	5.23 (4.42, 6.13)	0.079	7
placebo	9.36 (8.03, 10.82)	0.150	7	2.01 (1.38, 2.82)	0.080	7	4.97 (3.93, 6.18)	0.078	8

EX5BID: exenatide 5 μg twice daily; EX10BID: exenatide 10 μg twice daily; EX2QW: exenatide 2 mg once weekly; LIR0.6: liraglutide 0.6 mg once daily; LIR1.2: liraglutide 1.2 mg once daily; LIR1.8: liraglutide 1.8 mg once daily. Ranking: probability of being the worst treatment, of being the second worst, the third worst and so on, among the 8 comparisons. CT: conventional treatment. SUCRA: surface under the cumulative ranking curve.